Project Grant R43AI167567

Award Date 7/8/22
Completion Date 6/30/24
Dollars Obligated $461K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This National Science Foundation (NSF) Project Grant award for $380,074, awarded on September 1, 2024, aims to develop a platform for instrument-free, easy-to-interpret quantitative analysis of molecular biomarkers. The project will produce a general methodology adaptable to a range of molecular targets, including potential new agents. The key products to be delivered include: A "yes/no" output for quantitative measurement, enabled through stoichiometry and negative cooperativity-based...
New Horizon Biotech Inc. received a $256,000 National Science Foundation SBIR Phase I Project Grant to determine performance characteristics during cultivation of living organisms in a novel single-use horizontal modular and pressurizable microbial fermentor. The funding period is from February 15, 2021 through May 31, 2023 under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084). This program seeks to advance science, engineering, and technology innovations to address...
This $275,000 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program supports the development of a label-free, high-resolution, high-throughput protein screening platform called Vibrational Spectroscopy with Metasurface Optics (VISMO). The technology aims to enable simultaneous, minute-scale measurement of millions of protein samples, which would dramatically improve the lengthy and costly cycles...
This Project Grant award from the National Institutes of Health (NIH) Research Infrastructure Programs (CFDA 93.351) provides $270,428 to TEO Therapeutics Incorporated, a small disadvantaged business, to develop a biomimetic platform for more efficient pharmaceutical drug development in oncology. The key products and services to be delivered include: Refining and testing a proof-of-concept hardware product line for a Shell-Free Quail Xenograft Assay, optimizing throughput and assessing...
This $295,308 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), will support the development and validation of a novel class of scanning probe microscopy (SPM) probes for rapid identification of infectious disease agents. The awardee, Actoprobe LLC, aims to dramatically improve the sensitivity and spatial resolution of scanning...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development of a novel in-line biomanufacturing process analytical technology tool. The $302,417 award to Physical Sciences Inc. (PSI), in collaboration with the University of Massachusetts Lowell (UML), aims to enable real-time monitoring of biomolecules in large-scale bioreactors for gene therapy manufacturing. The technology...
This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), will fund the development of living biosensors capable of detecting and analyzing DNA at the single-base level without requiring sample purification or specialized equipment. The $565,614 award, made on April 5, 2025, will support the University of California, San...
This $350,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports the development and demonstration of a novel, enzyme-based, single-molecule protein sequencing system by Electronic Biosciences, Inc. The innovative platform aims to leverage enzymatic processing and advanced bioinformatics to enable scalable, multiplexed protein sequencing with high accuracy and throughput. During this Phase I...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training program provides $306,860 to Mixedlcmedia LLC, a small disadvantaged business, to develop and evaluate a prototype ultra-low flow liquid chromatography platform based on their proprietary porous layer open-tubular (PLOT) and monolithic nanocolumn technologies. The goal is to create a commercialization-ready LC system that enables deep proteomic...
This $306,872 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the development of a commercial prototype for Fluid Discovery, Inc.'s "Universal Platform for Ultrahigh-Throughput Biocatalyst Evolution with Micro-Mass Spectrometry." This transformative screening platform combines scalable hardware, label-free mass spectrometry, and advanced computational techniques to...

HELIOQUANT: A PLATFORM FOR FAST, LABEL-FREE, AUTOMATED EVALUATION OF BIOBURDEN - ABSTRACT BIOBURDEN CONSTITUTES A KEY COMPONENT OF ENVIRONMENTAL MONITORING PROGRAMS IN BIOMANUFACTURING FACILITIES, WHERE ROUTINE TESTING ALLOWS MANUFACTURERS TO ASSESS THE EFFICIENCY OF THE CLEANING AND DECONTAMINATION OF PACK- AGING, PRODUCT COMPONENTS, AND WORKSURFACES. HELIOWAVE TECHNOLOGIES, LLC, IS DEDICATED TO REVOLUTIONIZING BIOBURDEN TESTING BY DEVELOPING PRODUCTS THAT DRAMATICALLY INCREASE THE SPEED, EFFICIENCY, AND USABILITY, WHILE LOWERING THE COST OF BIOBURDEN TESTING FOR MATERIALS AND PRODUCTS USED IN THE BIOMEDICAL INDUSTRY. THE UNDERLYING APPROACH USED FOR BIOBURDEN TESTING-THE ASSESSMENT OF MICROBIAL GROWTH ON SOLID MEDIA-- HAS REMAINED UN- CHANGED FOR A CENTURY. HELIOWAVE TECHNOLOGIES, LLC, IS DEVELOPING HELIOQUANTTM, A NOVEL BIOBURDEN TESTING TECHNOLOGY PLATFORM THAT WILL REPLACE OUTDATED METHODS BY COMBINING ADVANCES IN TWO BROAD TECHNOLOGICAL AREAS, DROPLET MICROFLUIDICS AND IMPEDANCE DETECTION, TO DELIVER A COMPELLING BIOBURDEN TESTING SOLUTION. DROPLET MICRO- FLUIDICS SYSTEMS USE PICO-LITER-VOLUME WATER-IN-OIL EMULSION DROPLETS THAT FUNCTION AS CELL-ENCAPSULATED BIOREAC- TORS FOR THE PERFORMANCE OF LOW COST, RAPID, SINGLE-CELL-RESOLUTION BIOLOGICAL ASSAYS. IMPEDANCE SPECTROSCOPY- BASED CELL DETECTION IS LABEL-FREE, CAN DETECT BROAD RANGES OF MICROORGANISMS, AT HIGH SPEED. OVER THE PAST DECADE, THE COMPANY'S ACADEMIC PARTNERS HAVE SUBSTANTIALLY ADVANCED THE BASIC SCIENCE AND ENGINEERING THAT SUPPORTS THE DEVELOPMENT OF A SYSTEM THAT INTEGRATES INNOVATIONS IN DROPLET MICROFLUIDICS AND IMPEDANCE MICROS- COPY FOR BIOBURDEN TESTING. THE PROPOSED HELIOQUANTTM SYSTEM, WHICH LEVERAGES THIS EXPERTISE AND INNOVA- TIONS, WILL DELIVER DRAMATIC REDUCTIONS IN COST AND TESTING TIMES, RESPECTIVELY, FOR BIOBURDEN EVALUATION. WITH THESE IDEAS IN MIND, THE OVERARCHING TECHNICAL OBJECTIVE OF THIS PROPOSAL IS TO PROTOTYPE THE HELIOQUANTTM BIOBURDEN TESTING PLATFORM. TO ACHIEVE THIS GOAL, TWO SPECIFIC AIMS WILL BE PURSUED: (1). TO ADVANCE THE DEVELOPMENT OF THE DROPLET MICROFLUIDIC MODULE (HQ-DMMTM) OF THE HELIOQUANTTM SYSTEM; (2) TO ADVANCE THE DEVELOPMENT OF THE IMPEDANCE DETECTION MODULE (HQ-IDMTM) OF THE HELIOQUANTTM SYSTEM. THE OUTCOME OF THE PROPOSED WORK WILL BE THE DEVELOPMENT OF THE HELIOQUANTTM PROTOTYPE FOR BIOBURDEN ASSESSMENT. THE PROPOSED WORK WILL ALSO IDENTIFY TECHNICAL STRENGTHS AND LIMITATIONS (IF ANY) OF THE PROPOSED INTEGRATED SYSTEM, AND THEREBY SET THE STAGE FOR DEVELOPING A "MANUFACTURE READY" INTEGRATED HELIOQUANTTM PRODUCT IN PHASE II OF THE NIH SBIR PROGRAM.

Posted 7/8/22